文献速递药疹与重症皮肤不良反应

Stevens-Johnson综合征/中毒性表皮坏死松解症中改进致病药物识别的需求评估

Assessment of Need for Improved Identification of a Culprit Drug in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
PubMed 文献 · JAMA Dermatol · 2023-01-01

这项回顾性队列研究纳入48例经临床和组织学确诊的SJS/TEN重叠或TEN患者,描述性分析潜在致病药物、患者过敏清单及当前识别方法。结果显示当前方法倾向于过度标注可能非致病药物为过敏,而较少遗漏可能致病药物;采用系统化无偏方法可能改善识别,但最终仍需诊断性检测。

要点

  • 当前识别致病药物主要依赖对高知名度药物的启发式判断和用药时间。
  • 医师仅将17例标注为单一致病药物过敏,而所有患者过敏清单共添加104种药物。
  • 算法与医师判断在28例中不一致,额外标注9种医师遗漏药物并清除43种医师标注的过敏药物。

核心结论

  • 当前识别SJS/TEN致病药物的方法倾向于过度标注患者对可能非致病药物过敏,而较少遗漏可能致病药物。
  • 采用系统化无偏方法可能改善致病药物识别,但最终仍需诊断性检测。

研究设计与样本

  • 回顾性队列研究,历时18年(2000年1月至2018年7月),在Brigham and Women's Hospital和Massachusetts General Hospital(波士顿)进行。
  • 纳入48例经临床和组织学确诊的SJS/TEN重叠和TEN患者。

主要发现

  • 48例患者中29例女性(60.4%);4例亚洲人(8.3%)、6例黑人(12.5%)、5例西班牙裔(10.4%)、25例白人(52.1%);中位年龄40岁(范围1-82岁)。
  • 疾病发作时每位患者平均用药数为6.5(标准差4.7)种。
  • 医师将17例患者标注为对单一致病药物过敏;所有患者过敏清单共添加104种药物。
  • 医师方法主要依赖对高知名度药物的启发式识别和药物暴露时间。
  • 使用经过审核的药物风险数据库提高了敏感性。

关键数值与推荐

  • 医师将17例患者标注为对单一致病药物过敏,而所有患者过敏清单共添加104种药物。
  • Algorithm for Drug Causality for Epidermal Necrolysis评分在28例中不一致,额外标注9种医师遗漏的药物,并清除43种医师标注为过敏的药物。
  • 人类白细胞抗原检测可能影响20例。

临床怎么用

  • 当前基于临床判断的致病药物识别方法可能导致患者被过度标注为对可能非致病药物过敏。
  • 采用经过审核的药物风险数据库可能提高识别敏感性。
  • 系统化无偏方法可能改善致病药物识别,但最终仍需诊断性检测。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe hypersensitivity reaction. Identifying a culprit drug is critical for patient care, yet identification is based on clinical judgment. Data are limited on the accuracy in or approach to identifying a culprit drug. OBJECTIVE: To evaluate patient allergy list outcomes, current approaches in identifying culprit drugs, and potential methods of improving culprit drug identification. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study spanned 18 years (January 2000 to July 2018), was conducted at Brigham and Women's Hospital and Massachusetts General Hospital (Boston), and included patients with clinically and histologically confirmed cases of SJS/TEN overlap and TEN. MAIN OUTCOMES AND MEASURES: This study descriptively analyzed potential culprits to SJS/TEN, patients' allergy lists, and currently used approaches that led to those lists. It then tested the theoretical contribution of incorporating various parameters to allergy list outcomes. RESULTS: Of 48 patients (29 women [60.4%]; 4 Asian [8.3%], 6 Black [12.5%], 5 Hispanic [10.4%], and 25 White [52.1%] individuals; median age, 40 years [range, 1-82 years]), the mean (SD) number of drugs taken per patient at disease onset was 6.5 (4.7). Physicians labeled 17 patients as allergic to a single culprit drug. Comparatively, 104 drugs were added to allergy lists across all patients. Physicians' approaches relied largely on heuristic identification of high-notoriety drugs and the timing of drug exposure. Use of a vetted database for drug risk improved sensitivity. Algorithm for Drug Causality for Epidermal Necrolysis scoring was discordant in 28 cases, labeling an additional 9 drugs missed by physicians and clearing 43 drugs labeled as allergens by physicians. Human leukocyte antigen testing could have potentially affected 20 cases. Consideration of infection as a culprit was limited. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that currently used approaches to identify culprit drugs in SJS/TEN are associated with overlabeling patients allergic to likely nonculprit drugs and less commonly missed possible culprit drugs. Incorporation of a systematized unbiased approach could potentially improve culprit drug identification, although ultimately a diagnostic test is necessary.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Li DJ, Velasquez GA, Romar GA, et al. Assessment of Need for Improved Identification of a Culprit Drug in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. JAMA Dermatol. 2023. PMID: 37342052. doi:10.1001/jamadermatol.2023.1693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。